<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103740</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446H2305</org_study_id>
    <secondary_id>ZOL446K2305</secondary_id>
    <nct_id>NCT00103740</nct_id>
    <nct_alias>NCT00051649</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period</brief_title>
  <official_title>Randomized, Double-Blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observation Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The primary objective of this core study was to show non-inferiority of zoledronic acid to
      risedronate, with respect to the proportion of patients who achieved therapeutic response.
      The extended observation period included participants of the core study who responded to
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Had Therapeutic Response at 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>A therapeutic response was defined as a reduction of at least 75% from baseline (Visit 1) in serum alkaline phosphatase (SAP) excess (difference between measured level and midpoint to the normal range) or normalization of SAP at the end of six months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative Change in Serum Alkaline Phosphatase in U/L at Day 28</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>The percent change in serum alkaline phosphatase from baseline to Day 28 was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change in Serum C-telopeptide (CTx) in ng/mL at Day 10</measure>
    <time_frame>Baseline and day 10</time_frame>
    <description>The percent change in serum C-telopeptide from baseline to Day 10 was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change in Urine α-CTx in ug/mmol at Day 10</measure>
    <time_frame>Baseline and day 10</time_frame>
    <description>The percent change in urine α-CTx from baseline to Day 10 was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Therapeutic Response</measure>
    <time_frame>182 days</time_frame>
    <description>Therapeutic response was defined as a reduction of at least 75% from baseline in serum alkaline phosphatase excess (difference between measured level and midpoint to the normal range) or normalization of serum alkaline phosphatase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Normalization of serum alkaline phosphatase occurred if the serum alkaline phosphatase measurement fell within the normal range. Central laboratory reference ranges for serum alkaline phosphatase: 31-110 U/L (female &amp; male 20-58 years) and 35-115 U/L (female &amp; male &gt;58 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Severity at Day 182</measure>
    <time_frame>Baseline and day 182</time_frame>
    <description>Change in pain severity score from Brief Pain Inventory-Short Form (BPI-SF). This scale values are 0 to 10, a lower score means little to no pain while a higher score means greater pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Interference at Day 182</measure>
    <time_frame>Baseline and day 182</time_frame>
    <description>Change in pain interference score from Brief Pain Inventory-Short Form (BPI-SF). This scale values are 0 to 10, a lower score means little to no pain while a higher score means greater pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period</measure>
    <time_frame>8 years was the maximum</time_frame>
    <description>Extended observation period. A therapeutic response is defined as a reduction of at least 75% from baseline in serum alkaline phosphatase excess or normalization of serum alkaline phosphatase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Partial Disease Relapse During the Extended Observation Period</measure>
    <time_frame>8 years was the maximum</time_frame>
    <description>Extended observation period. A partial disease relapse was defined as an increase in serum alkaline phosphatase &gt;= 50% from the serum alkaline phosphatase measurement at Month 6 and at least 1.25 times the upper normal limit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Disease Relapse During the Extended Observation Period</measure>
    <time_frame>8 years was maximum</time_frame>
    <description>Extended observation period. A disease relapse was defined as the occurrence of a serum alkaline phosphatase level that was &gt;= 80% of baseline serum alkaline phosphatase value.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Paget's Disease of Bone</condition>
  <arm_group>
    <arm_group_label>Zoledronic acid and placebo to risedronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risedronate and placebo to zoledronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>5 mg zoledronic acid in 5 mL of sterile water for infusion</description>
    <arm_group_label>Zoledronic acid and placebo to risedronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to zoledronic acid</intervention_name>
    <description>5 mL of sterile water for infusion</description>
    <arm_group_label>Risedronate and placebo to zoledronic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate</intervention_name>
    <description>30mg oral tablets overencapsulated to match the placebo capsules</description>
    <arm_group_label>Risedronate and placebo to zoledronic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to risedronate</intervention_name>
    <description>oral capsules</description>
    <arm_group_label>Zoledronic acid and placebo to risedronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium and vitamin D supplements</intervention_name>
    <description>Calcium and vitamin D supplements were supplied</description>
    <arm_group_label>Zoledronic acid and placebo to risedronate</arm_group_label>
    <arm_group_label>Risedronate and placebo to zoledronic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  30 years or older

          -  SAP 2 times ULN

          -  Confirmed diagnosis of Paget's disease of the bone (by x-ray, magnetic resonance
             imaging, computerized tomography, radioisotope imaging, etc.).

          -  90 days washout calcitonin

          -  180 day washout bisphosphonate

        Exclusion Criteria:

          -  Allergic reaction to bisphosphonates

          -  History of upper GI disorders

          -  History of iritis, uveitis

          -  Calculated creatinine clearance &lt; 30 ml/min at baseline

          -  Evidence of vitamin D deficiency

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53592</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fitzroy</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kogarah</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Newcastle</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>St. Leonards</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dreux Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wirzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2005</study_first_submitted>
  <study_first_submitted_qc>February 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2005</study_first_posted>
  <results_first_submitted>April 5, 2012</results_first_submitted>
  <results_first_submitted_qc>April 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2012</results_first_posted>
  <last_update_submitted>May 29, 2012</last_update_submitted>
  <last_update_submitted_qc>May 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Zoledronic acid, risedronate, Paget's disease of bone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Osteitis Deformans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>371 patients were screened. 185 patients were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Zoledronic Acid and Placebo to Risedronate</title>
          <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
        </group>
        <group group_id="P2">
          <title>Risedronate and Placebo to Zoledronic Acid</title>
          <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 - Core</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 - Extended Observation Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9">Includes patients retreated for Paget's disease and patients discontinued when sponsor ended study</participants>
                <participants group_id="P2" count="27">Includes patients retreated for Paget's disease and patients discontinued when sponsor ended study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew for nonclinical reason</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical reason other than Paget's</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Amendment 6 informed consent not signed</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zoledronic Acid and Placebo to Risedronate</title>
          <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
        </group>
        <group group_id="B2">
          <title>Risedronate and Placebo to Zoledronic Acid</title>
          <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
            <count group_id="B2" value="93"/>
            <count group_id="B3" value="185"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.3" spread="9.42"/>
                    <measurement group_id="B2" value="68.2" spread="11.15"/>
                    <measurement group_id="B3" value="69.8" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Had Therapeutic Response at 6 Months</title>
        <description>A therapeutic response was defined as a reduction of at least 75% from baseline (Visit 1) in serum alkaline phosphatase (SAP) excess (difference between measured level and midpoint to the normal range) or normalization of SAP at the end of six months.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>Modified intent to treat population: all randomized patients with both baseline and at least one post-baseline serum alkaline phosphatase measurement. Missing values at 6 months were imputed using the last post-baseline measurement prior to 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid and Placebo to Risedronate</title>
            <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
          <group group_id="O2">
            <title>Risedronate and Placebo to Zoledronic Acid</title>
            <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Had Therapeutic Response at 6 Months</title>
          <description>A therapeutic response was defined as a reduction of at least 75% from baseline (Visit 1) in serum alkaline phosphatase (SAP) excess (difference between measured level and midpoint to the normal range) or normalization of SAP at the end of six months.</description>
          <population>Modified intent to treat population: all randomized patients with both baseline and at least one post-baseline serum alkaline phosphatase measurement. Missing values at 6 months were imputed using the last post-baseline measurement prior to 6 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change in Serum Alkaline Phosphatase in U/L at Day 28</title>
        <description>The percent change in serum alkaline phosphatase from baseline to Day 28 was measured.</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>Intent-to-treat population: all randomized patients. Participants with observations at baseline and 28 days were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid and Placebo to Risedronate</title>
            <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
          <group group_id="O2">
            <title>Risedronate and Placebo to Zoledronic Acid</title>
            <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Serum Alkaline Phosphatase in U/L at Day 28</title>
          <description>The percent change in serum alkaline phosphatase from baseline to Day 28 was measured.</description>
          <population>Intent-to-treat population: all randomized patients. Participants with observations at baseline and 28 days were included in this analysis.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.1" spread="14.55"/>
                    <measurement group_id="O2" value="-24.3" spread="18.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change in Serum C-telopeptide (CTx) in ng/mL at Day 10</title>
        <description>The percent change in serum C-telopeptide from baseline to Day 10 was measured.</description>
        <time_frame>Baseline and day 10</time_frame>
        <population>Intent-to-treat population: all randomized patients. Participants with observations at baseline and day 10 were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid and Placebo to Risedronate</title>
            <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
          <group group_id="O2">
            <title>Risedronate and Placebo to Zoledronic Acid</title>
            <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Serum C-telopeptide (CTx) in ng/mL at Day 10</title>
          <description>The percent change in serum C-telopeptide from baseline to Day 10 was measured.</description>
          <population>Intent-to-treat population: all randomized patients. Participants with observations at baseline and day 10 were included in this analysis.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74.2" spread="123.73"/>
                    <measurement group_id="O2" value="-40.1" spread="34.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change in Urine α-CTx in ug/mmol at Day 10</title>
        <description>The percent change in urine α-CTx from baseline to Day 10 was measured.</description>
        <time_frame>Baseline and day 10</time_frame>
        <population>Intent-to-treat population: all randomized patients. Participants with observations at baseline and day 10 were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid and Placebo to Risedronate</title>
            <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
          <group group_id="O2">
            <title>Risedronate and Placebo to Zoledronic Acid</title>
            <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Urine α-CTx in ug/mmol at Day 10</title>
          <description>The percent change in urine α-CTx from baseline to Day 10 was measured.</description>
          <population>Intent-to-treat population: all randomized patients. Participants with observations at baseline and day 10 were included in this analysis.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-87.5" spread="39.33"/>
                    <measurement group_id="O2" value="-28.7" spread="68.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Therapeutic Response</title>
        <description>Therapeutic response was defined as a reduction of at least 75% from baseline in serum alkaline phosphatase excess (difference between measured level and midpoint to the normal range) or normalization of serum alkaline phosphatase.</description>
        <time_frame>182 days</time_frame>
        <population>Intent-to-treat population: all randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid and Placebo to Risedronate</title>
            <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
          <group group_id="O2">
            <title>Risedronate and Placebo to Zoledronic Acid</title>
            <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Therapeutic Response</title>
          <description>Therapeutic response was defined as a reduction of at least 75% from baseline in serum alkaline phosphatase excess (difference between measured level and midpoint to the normal range) or normalization of serum alkaline phosphatase.</description>
          <population>Intent-to-treat population: all randomized patients.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="33" upper_limit="65"/>
                    <measurement group_id="O2" value="91" lower_limit="64" upper_limit="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28</title>
        <description>Normalization of serum alkaline phosphatase occurred if the serum alkaline phosphatase measurement fell within the normal range. Central laboratory reference ranges for serum alkaline phosphatase: 31-110 U/L (female &amp; male 20-58 years) and 35-115 U/L (female &amp; male &gt;58 years).</description>
        <time_frame>Day 28</time_frame>
        <population>Intent-to-treat population: all randomized patients. Participants with observations at day 28 were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid and Placebo to Risedronate</title>
            <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
          <group group_id="O2">
            <title>Risedronate and Placebo to Zoledronic Acid</title>
            <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28</title>
          <description>Normalization of serum alkaline phosphatase occurred if the serum alkaline phosphatase measurement fell within the normal range. Central laboratory reference ranges for serum alkaline phosphatase: 31-110 U/L (female &amp; male 20-58 years) and 35-115 U/L (female &amp; male &gt;58 years).</description>
          <population>Intent-to-treat population: all randomized patients. Participants with observations at day 28 were included in this analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Severity at Day 182</title>
        <description>Change in pain severity score from Brief Pain Inventory-Short Form (BPI-SF). This scale values are 0 to 10, a lower score means little to no pain while a higher score means greater pain.</description>
        <time_frame>Baseline and day 182</time_frame>
        <population>Intent-to-treat population: all randomized patients. Participants with observations at baseline and day 182 were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid and Placebo to Risedronate</title>
            <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
          <group group_id="O2">
            <title>Risedronate and Placebo to Zoledronic Acid</title>
            <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Severity at Day 182</title>
          <description>Change in pain severity score from Brief Pain Inventory-Short Form (BPI-SF). This scale values are 0 to 10, a lower score means little to no pain while a higher score means greater pain.</description>
          <population>Intent-to-treat population: all randomized patients. Participants with observations at baseline and day 182 were included in this analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.74"/>
                    <measurement group_id="O2" value="-0.1" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Interference at Day 182</title>
        <description>Change in pain interference score from Brief Pain Inventory-Short Form (BPI-SF). This scale values are 0 to 10, a lower score means little to no pain while a higher score means greater pain.</description>
        <time_frame>Baseline and day 182</time_frame>
        <population>Intent-to-treat population: all randomized patients. Participants with observations at baseline and day 182 were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid and Placebo to Risedronate</title>
            <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
          <group group_id="O2">
            <title>Risedronate and Placebo to Zoledronic Acid</title>
            <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Interference at Day 182</title>
          <description>Change in pain interference score from Brief Pain Inventory-Short Form (BPI-SF). This scale values are 0 to 10, a lower score means little to no pain while a higher score means greater pain.</description>
          <population>Intent-to-treat population: all randomized patients. Participants with observations at baseline and day 182 were included in this analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.97"/>
                    <measurement group_id="O2" value="0.0" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period</title>
        <description>Extended observation period. A therapeutic response is defined as a reduction of at least 75% from baseline in serum alkaline phosphatase excess or normalization of serum alkaline phosphatase.</description>
        <time_frame>8 years was the maximum</time_frame>
        <population>Extended modified Intent-to-treat population: patients who had at least one serum alkaline phosphatase measurement during the extension period.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid and Placebo to Risedronate</title>
            <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
          <group group_id="O2">
            <title>Risedronate and Placebo to Zoledronic Acid</title>
            <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period</title>
          <description>Extended observation period. A therapeutic response is defined as a reduction of at least 75% from baseline in serum alkaline phosphatase excess or normalization of serum alkaline phosphatase.</description>
          <population>Extended modified Intent-to-treat population: patients who had at least one serum alkaline phosphatase measurement during the extension period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="2218"/>
                    <measurement group_id="O2" value="42" lower_limit="344" upper_limit="1605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Partial Disease Relapse During the Extended Observation Period</title>
        <description>Extended observation period. A partial disease relapse was defined as an increase in serum alkaline phosphatase &gt;= 50% from the serum alkaline phosphatase measurement at Month 6 and at least 1.25 times the upper normal limit.</description>
        <time_frame>8 years was the maximum</time_frame>
        <population>Extended modified Intent-to-treat population: patients who had at least one serum alkaline phosphatase measurement during the extension period.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid and Placebo to Risedronate</title>
            <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
          <group group_id="O2">
            <title>Risedronate and Placebo to Zoledronic Acid</title>
            <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Partial Disease Relapse During the Extended Observation Period</title>
          <description>Extended observation period. A partial disease relapse was defined as an increase in serum alkaline phosphatase &gt;= 50% from the serum alkaline phosphatase measurement at Month 6 and at least 1.25 times the upper normal limit.</description>
          <population>Extended modified Intent-to-treat population: patients who had at least one serum alkaline phosphatase measurement during the extension period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="2218"/>
                    <measurement group_id="O2" value="37" lower_limit="373" upper_limit="1652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Disease Relapse During the Extended Observation Period</title>
        <description>Extended observation period. A disease relapse was defined as the occurrence of a serum alkaline phosphatase level that was &gt;= 80% of baseline serum alkaline phosphatase value.</description>
        <time_frame>8 years was maximum</time_frame>
        <population>Extended modified Intent-to-treat population: patients who had at least one serum alkaline phosphatase measurement during the extension period.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid and Placebo to Risedronate</title>
            <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
          <group group_id="O2">
            <title>Risedronate and Placebo to Zoledronic Acid</title>
            <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Disease Relapse During the Extended Observation Period</title>
          <description>Extended observation period. A disease relapse was defined as the occurrence of a serum alkaline phosphatase level that was &gt;= 80% of baseline serum alkaline phosphatase value.</description>
          <population>Extended modified Intent-to-treat population: patients who had at least one serum alkaline phosphatase measurement during the extension period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="15" lower_limit="1084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety population consisted of all randomized patients who were exposed to study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zoledronic Acid</title>
          <description>Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
        </group>
        <group group_id="E2">
          <title>Risedronate</title>
          <description>Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enterobacter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

